Brief: Sorrento Announces FDA Authorization To Proceed With Phase 1 Study Of Intranasal STI-9199

Sorrento Therapeutics

02/03/2022 16:25

March 2 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO ANNOUNCES FDA AUTHORIZATION TO PROCEED WITH PHASE
1
STUDY OF INTRANASAL STI-9199 (COVISHIELD), A POTENT
NEUTRALIZATION ANTIBODY AGAINST COVID-19 VIRUSES
    * SORRENTO THERAPEUTICS - PLANS TO DISCUSS WITH FDA MOST
APPROPRIATE END-POINTS FOR PIVOTAL STUDY THAT COULD RESULT IN AN
EUA
    * SORRENTO THERAPEUTICS INC - PHASE 1 STUDY WILL BE AT A
SINGLE
CLINICAL SITE IN SAN DIEGO
    * SORRENTO THERAPEUTICS - STI-9199 INITIAL TRIALS EXPECTED
TO BE
FOLLOWED BY MULTINATIONAL PHASE 2/3 TRIAL IN BOTH MILD AND
MODERATE COVID-19 PATIENTS
    * SORRENTO THERAPEUTICS INC - PHASE 1 STUDY WILL BE FOLLOWED
BY
MULTINATIONAL (USA, UK AND MEXICO) PHASE 2/3 TRIALS

Source text for Eikon:  ID:nGNX1G3Y5w 
Further company coverage:  SRNE.O 

 ((Reuters.briefs@thomsonreuters.com;))